八旬患者中复杂腔内动脉瘤修复术相比肾下腔内修复术围手术期死亡率更高但晚期死亡率无差异
单中心回顾性研究纳入2009至2015年接受择期EVAR的80岁及以上腹主动脉瘤患者103例(肾下型68例、复杂型35例),平均随访21个月。复杂EVAR组30天死亡率显著更高(8.6% vs 0%,P=0.03),但晚期再干预与全因死亡率无显著差异;瘤体大于75 mm与肾功能不全是晚期死亡的独立危险因素。
要点
- 八旬患者复杂EVAR组30天死亡率为8.6%,肾下EVAR组为0%(P=0.03)。
- 两组主要不良事件(P=0.795)与晚期再干预(P=0.232)无显著差异。
- 瘤体大于75 mm(HR 4.9,95%CI 4.6-48.2)与肾功能不全是晚期死亡的独立危险因素。
核心结论
- 八旬患者中复杂EVAR相比肾下EVAR围手术期死亡率更高,但晚期再干预需求与全因死亡率无显著差异。
- 较大的动脉瘤和慢性肾脏病预示EVAR后晚期死亡风险更高,与腹主动脉瘤复杂程度无关。
- 作者认为在向老年患者提供腔内治疗时应考虑这些患者相关因素。
研究设计与样本
- 单中心回顾性研究,使用2009至2015年连续接受择期EVAR治疗腹主动脉瘤患者数据库。
- 仅纳入80岁及以上患者,共103例(肾下EVAR组68例,复杂EVAR组35例),平均随访21个月。
- 复杂EVAR组采用烟囱/潜望镜或开窗技术,肾下EVAR组为不涉及肾或内脏动脉的动脉瘤修复。
主要发现
- 复杂EVAR组共置入75枚分支支架(肾动脉59枚、腹腔干11枚、肠系膜上动脉5枚),最新随访时靶血管通畅率为98.2%。
- 复杂EVAR组男性比例更高(82.8% vs 60.2%,P=0.02),肾功能不全患病率更高(71.4% vs 44.2%,P=0.008)。
- 复杂EVAR组30天死亡率显著更高(8.6% vs 0%,P=0.03)。
- 两组主要不良事件(P=0.795)与晚期再干预(P=0.232)无显著差异。
- 肾下EVAR组瘤囊增长超过10 mm更常见(17.6% vs 2.8%,P=0.039);IA型内漏(肾下组5.7%,复杂组4.9%)与II型内漏(肾下组32.3%,复杂组25.7%)在两组中同样常见。
临床怎么用
- 作者认为在向老年患者提供腔内治疗时应考虑较大的动脉瘤和慢性肾脏病等患者相关因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As our collective experience with complex endovascular aneurysm repair (EVAR) has grown, an increasing number of older patients are being offered endovascular repair of juxtarenal aneurysms. Outcomes after complex EVAR in this older subpopulation are not well-described. We sought to specifically evaluate clinical outcomes after complex EVAR compared with infrarenal EVAR in a cohort of octogenarians. METHODS: A single-center retrospective review was conducted using a database of consecutive patients treated with elective EVAR for abdominal aortic aneurysms (AAAs) between 2009 and 2015. Only patients 80 years of age or older were included. Patients in the complex EVAR group were treated with either snorkel/chimney or fenestrated techniques, whereas infrarenal EVAR consisted of aneurysm repair without renal or visceral involvement. Relevant demographic, anatomic, and device variables, and clinical outcomes were collected. RESULTS: There were 103 patients (68 infrarenal, 35 complex) treated within the study period with a mean follow-up of 21 months. A total of 75 branch grafts were placed (59 renal, 11 celiac, 5 superior mesenteric artery) in the complex group, with a target vessel patency of 98.2% at latest follow-up. Patients undergoing complex EVAR were more likely to be male (82.8% vs 60.2%; P = .02) and have a higher prevalence of renal insufficiency (71.4% vs 44.2%; P = .008). The 30-day mortality was significantly greater in patients treated with complex EVAR (8.6% vs 0%; P = .03). There were no differences in major adverse events (P = .795) or late reintervention (P = .232) between groups. Interestingly, sac growth of more than 10 mm was noted to be more frequent with infrarenal EVAR (17.6% vs 2.8%; P = .039). However, both type IA (5.7% infrarenal; 4.9% complex) and type II endoleaks (32.3% infrarenal; 25.7% complex) were found to be equally common in both groups. Complex EVAR was not associated with increased all-cause mortality at latest follow-up (P = .322). Multivariable Cox modeling demonstrated that AAAs greater than 75 mm in diameter (hazard ratio; 4.9; 95% confidence interval, 4.6-48.2) and renal insufficiency (hazard ratio, 3.71; 95% confidence interval, 1.17-11.6) were the only independent risk factors of late death. CONCLUSIONS: Complex EVAR is associated with greater perioperative mortality compared with infrarenal EVAR among octogenarians. However, late outcomes, including the need for reintervention and all-cause mortality, are not significantly different. Larger aneurysms and chronic kidney disease portends greater risk of late death after EVAR, regardless of AAA complexity. These patient-related factors should be considered when offering endovascular treatment to older patients.
引用
- Tran K, Lee AM, McFarland GE, et al. Complex endovascular aneurysm repair is associated with higher perioperative mortality but not late mortality compared with infrarenal endovascular aneurysm repair among octogenarians. J Vasc Surg. 2018. PMID: 29970274. doi:10.1016/j.jvs.2018.04.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。